Cargando…

Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation

BRAF mutation is one of the important driver oncogene in non‐small‐cell lung cancer (NSCLC). Data on Chinese patients with BRAF‐mutant NSCLC are inadequate. Hence, we conducted this study to investigate the clinicopathologic features and outcomes of Chinese patients with NSCLC and BRAF mutations. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Xi, Zhang, Zengli, Jiang, Tao, Li, Xuefei, Zhao, Chao, Su, Bo, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345676/ https://www.ncbi.nlm.nih.gov/pubmed/28135039 http://dx.doi.org/10.1002/cam4.1014

Ejemplares similares

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma
por: Shan, Ling, et al.
Publicado: (2015)

Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
por: Qiao, Meng, et al.
Publicado: (2022)

Gene mutation profiling in Chinese colorectal cancer patients and its association with clinicopathological characteristics and prognosis
por: Ye, Zu‐Lu, et al.
Publicado: (2019)

Clinicopathologic distribution of KRAS and BRAF mutations in a Chinese population with colorectal cancer precursor lesions
por: Yi, Chenghao, et al.
Publicado: (2016)

Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation
por: Ambrosini-Spaltro, Andrea, et al.
Publicado: (2023)

Prognostic value of PD‐L1 expression in combination with CD8(+) TILs density in patients with surgically resected non‐small cell lung cancer
por: Yang, Hui, et al.
Publicado: (2017)

BRAF mutation and its inhibitors in sarcoma treatment
por: Liu, Haotian, et al.
Publicado: (2020)

A large, single‐center, real‐world study of clinicopathological characteristics and treatment in advanced ALK‐positive non‐small‐cell lung cancer
por: Chen, Gang, et al.
Publicado: (2017)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

Expression of miRNAs in Papillary Thyroid Carcinomas Is Associated with BRAF Mutation and Clinicopathological Features in Chinese Patients
por: Sun, Yun, et al.
Publicado: (2013)

Clinicopathological characteristics and survival of spinal cord astrocytomas
por: Zhang, Yao‐Wu, et al.
Publicado: (2020)

Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis
por: Jiang, Tao, et al.
Publicado: (2016)

Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients
por: Zhao, Chao, et al.
Publicado: (2020)

The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients
por: Yang, Li-Bo, et al.
Publicado: (2015)

Former smokers with non‐small‐cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis
por: Zheng, Shanbo, et al.
Publicado: (2016)

Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene
por: Hino, Hitoshi, et al.
Publicado: (2019)

Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody
por: Song, Xinyu, et al.
Publicado: (2023)

The prevalence and prognostic value of KRAS co‐mutation subtypes in Chinese advanced non‐small cell lung cancer patients
por: Cai, Dongjing, et al.
Publicado: (2019)

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

Clinicopathological and prognostic value of S100A4 expression in non-small cell lung cancer: a meta-analysis
por: Zhang, Jing, et al.
Publicado: (2020)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
por: Moser, Justin C., et al.
Publicado: (2019)

AKT1 and BRAF mutations in pediatric aggressive fibromatosis
por: Meazza, Cristina, et al.
Publicado: (2016)

Risk factors for nicotine dependence in Chinese patients with lung cancer
por: Gu, Fen, et al.
Publicado: (2018)

Analysis of the clinicopathological characteristics, genetic phenotypes, and prognostic of pure mucinous adenocarcinoma
por: Chen, Zhencong, et al.
Publicado: (2019)

Age‐specific clinicopathological characteristics and prognostic analysis of neuroendocrine carcinomas of the gallbladder
por: Zhang, Zhiwei, et al.
Publicado: (2021)

The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients
por: Lin, Quan, et al.
Publicado: (2019)

Comprehensive analysis of age‐related somatic mutation profiles in Chinese young lung adenocarcinoma patients
por: Yang, Bo, et al.
Publicado: (2019)

Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single‐center retrospective study of 1,834 Chinese patients with Stage I–IV colorectal cancer
por: Guo, Tian‐An, et al.
Publicado: (2019)

EGFR‐mutated stage IV non‐small cell lung cancer: What is the role of radiotherapy combined with TKI?
por: Liu, Bailong, et al.
Publicado: (2021)

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
por: Zhang, Wenjing, et al.
Publicado: (2021)

Clinicopathological characteristics and survival outcomes in Paget disease: a SEER population‐based study
por: Zhao, Yang, et al.
Publicado: (2018)

Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B‐cell lymphoma
por: Tian, Tian, et al.
Publicado: (2020)

Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis
por: Bylsma, Lauren C., et al.
Publicado: (2019)

BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma
por: Henke, Lauren E, et al.
Publicado: (2015)

Anterior wall adenocarcinoma of bladder with similar clinicopathological and prognostic characteristics as common bladder carcinomas should not be treated as or classified into urachal adenocarcinomas
por: Zhou, Yu‐Wen, et al.
Publicado: (2021)

BRAF(V600E) mutation test on fine‐needle aspiration specimens of thyroid nodules: Clinical correlations for 4600 patients
por: Chen, Huang, et al.
Publicado: (2021)

Multicentric occurrence of multiple papillary thyroid carcinomas –HUMARA and BRAF mutation analysis
por: Nakazawa, Tadao, et al.
Publicado: (2015)

Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer
por: Bhateja, Priyanka, et al.
Publicado: (2019)

Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries
por: Guha, Avirup, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kbckto7imq50h0027g9qin47g9